Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director | November 03, 2025 | November 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TherapeuticsMD, Inc.
Report date November 03, 2025 · Filed November 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 8,500 |
Reported balance
After 2025-11-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-03 · Grant · Acquired 8,500 · Balance 8,500 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2025 Filed Nov 5, 2025 21:17 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-003783 · form4.xml · derivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSUs will vest on November 3, 2028. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:08 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000740 · form4.xml · derivative · entry 2 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the issuer. On February 18, 2025, the reporting person received 8,500 shares of common stock of the issuer in settlement of RSUs, which vested on July 17, 2024. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 02:08 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000740 · form4.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2024 Filed Aug 26, 2024 21:40 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 4,094 | $1.73 | $7,099.00 |
DisclosureSEC source: 0000905148-24-002363 · form4.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,016 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices of $1.69 through $1.75, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 22:18 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 1,200 | $1.70 | $2,038.56 |
DisclosureSEC source: 0000905148-24-002340 · form4.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,922 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices of $1.685 through $1.70, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth. Read SEC document |
| July 17, 2023 Filed Jul 19, 2023 21:27 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 8,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042763 · doc4.xml · derivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on July 17, 2024. Read SEC document |
| September 29, 2022 Filed Oct 3, 2022 22:39 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051955 · doc4.xml · derivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. F1 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer. The RSU's will vest on September 29, 2023. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 10:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 1,984 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046969 · doc4.xml · derivative · entry 2 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,984 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. F2 · shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. F3 · derivative.exercise_date: The RSUs vested on July 1, 2022. F3 · derivative.expiration_date: The RSUs vested on July 1, 2022. F1 · derivative.underlying_shares: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. F2 · derivative.underlying_shares: Each RSU represents a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 10:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 1,984 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046969 · doc4.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 18, 2022, the reporting person received 1,984 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on July 1, 2022. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 11:30 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 1,000,000 | $0.58 | $578,500.00 |
DisclosureSEC source: 0001209191-21-066002 · doc4.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,236,864 F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions with prices ranging from $0.5581 to $0.5850 for an average weighted purchase price of $0.5785. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2021 Filed Aug 19, 2021 10:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 900,000 | $0.72 | $648,000.00 |
DisclosureSEC source: 0001387131-21-008733 · ownership.xml · nonDerivative · entry 2 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,236,864 F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions with prices ranging from $0.715 to $0.727 for an average weighted purchase price of $0.72. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 10:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 100,000 | $0.77 | $77,000.00 |
DisclosureSEC source: 0001387131-21-008733 · ownership.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,864 F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions with prices ranging from $0.746 to $0.78 for an average weighted purchase price of $0.77. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 10, 2021 Filed Aug 13, 2021 01:31 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 96,864 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-008436 · ownership.xml · derivative · entry 2 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F2 · shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. F3 · derivative.exercise_date: The RSUs vested on June 18, 2021. F3 · derivative.expiration_date: The RSUs vested on June 18, 2021. F1 · derivative.underlying_shares: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F2 · derivative.underlying_shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| August 10, 2021 Filed Aug 13, 2021 01:31 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 96,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-008436 · ownership.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:59 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 99,174 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-007127 · ownership.xml · derivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,174 Underlying: Common Stock · 99,174 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 21:08 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 96,864 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-20-005816 · ownership.xml · derivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,864 Underlying: Common Stock · 96,864 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 20:25 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 47,500 | $1.45 | $68,875.00 |
DisclosureSEC source: 0001387131-20-005591 · ownership.xml · nonDerivative · entry 2 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 20:25 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 26,500 | $1.45 | $38,425.00 |
DisclosureSEC source: 0001387131-20-005591 · ownership.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,500 Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001387131-19-004585 · collins-form4_062019.xml · derivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-06-20 Read SEC document |
| May 13, 2019 Filed May 15, 2019 21:03 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | PurchaseCommon Stock | 30,000 | $3.33 | $99,870.00 |
DisclosureSEC source: 0001387131-19-003731 · collins-form4_051319.xml · nonDerivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.32 to $3.33, inclusive. The Reporting Person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001387131-18-003027 · collins-form4_070218.xml · derivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-07-02 Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 20:32 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001387131-17-003414 · collins-form4_062117.xml · derivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-06-21 Read SEC document |
| December 21, 2016 Filed Dec 23, 2016 00:04 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001387131-16-008704 · collins-form4_12212016.xml · derivative · entry 1 Collins Cooper C. · CIK 0001485508 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-12-20 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.